Ananda Scientific is a research-driven biotech company developing life-changing medicines to transform neuropsychiatric health. Our lead program is PTSD where we have two well powered phase-2 PTSD clinical trials nearing completion at high quality academic sites. We are in early discussions with the FDA to initiate a phase-2/3 PTSD trial by the end of 2025. Through a patented drug delivery technology developed at the Hebrew University in Jerusalem, we have overcome the primary challenge with CBD delivery i.e. poor absorption and inconsistent uptake. This delivery technology allows us to unmask the potential of CBD which was demonstrated in a Phase-1 PK study done head-to-head against Epidiolex®. The company is working on six phase-2 trials for multiple neuropsychiatric indications including PTSD, Opioid Use Disorder, Social Anxiety and Smoking Cessation. We have a strong patent estate covering global markets and have built a GxP compliant drug development infrastructure.